Last reviewed · How we verify
NCT04854343
SLPI for Prostate Cancer
trial testing Secretory leukocyte protease inhibitor (SLPI) in prostate cancer in Prostate Cancer in 280 participants. Status unknown.
1 December 2022
Quick facts
| Lead sponsor | University of Florence |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 280 |
| Start date | 1 December 2020 |
| Primary completion | 1 December 2022 |
| Estimated completion | 1 July 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Secretory leukocyte protease inhibitor (SLPI) in prostate cancer
- Determination of molecular alterations
- Secretory leukocyte protease inhibitor (SLPI) Healthy
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Prostatic Neoplasm — all drugs for Prostatic Neoplasm →
Sponsor
University of Florence
Who can join
18 and older, male only, with Prostate Cancer or Prostatic Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Exploratory study of SLPI expression in human prostate cancer patients This is a no-profit exploratory study about the expression of SLPI in human prostate cancer patients that will enroll about 200 patients admitted for suspect prostate cancer to Careggi University Hospital. We will verify whether an increase SLPI levels in the sera may serve as biomarker of cancer progression.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Potential of Extracellular Matrix- and Integrin Adhesion Complex-Related Molecules for Prostate Cancer Biomarker Discovery.
Samaržija I. · · 2023 · cited 13× · PMID 38255186 · DOI 10.3390/biomedicines12010079 -
TMPRSS2 as a Key Player in Viral Pathogenesis: Influenza and Coronaviruses.
Barros de Lima G, Nencioni E, Thimoteo F, Perea C, et al · · 2025 · cited 6× · PMID 39858469 · DOI 10.3390/biom15010075
Verify or expand the search:
- PubMed search for NCT04854343
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other University of Florence trials
Trials by the same sponsor.
- NCT06628921 — The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study) · recruiting
- NCT06123000 — Modified Widman Flap vs Fibre Retention Osseous Resective Surgery · NA · recruiting
- NCT06135753 — Psychosomatic Intervention in Fibromyalgia. · NA · recruiting
- NCT06086821 — Clinical Relevance of Different Time of Periodontal Re-evaluation · NA · completed
- NCT06884553 — Robotic Rehabilitation Vs Occupational Therapy Chronic Stroke Upper Limb Rehabilitation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04854343 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Florence
- Last refreshed: 9 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04854343.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing